Company intelligence / Profile preview

Beijing Anjianxi Pharmaceutical Technology Co., Ltd.

Ownership: Private
Development stage: Phase 1

Overview

Beijing Anjianxi Pharmaceutical Technology Co., Ltd. has at least one hundred clinical results associated with its name, indicating an active engagement in drug development or clinical research. However, no detailed outcomes or specific programs are publicly listed as of now.

Industry: Contract Research Organization

Drug pipeline

1 asset

R01

Phase 1

Indications: Non-small cell lung cancer, Colorectal cancer, Nasopharyngeal cancer, Solid tumors

Beyond the preview

Go deeper on Beijing Anjianxi Pharmaceutical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Anjianxi Pharmaceutical Technology Co., Ltd..

Explore the full profile